We’re a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we’re taking could succeed in defeating herpes by inducing antibodies that mediate the killing of infected cells. We’re strongly committed to this fight, and so far our work has been supported with unprecedented data in multiple preclinical models.
Location: United States, Florida
Employees: 11-50
Total raised: $56M
Founded date: 2015
Investors 4
| Date | Name | Website |
| - | Scientia V... | scientiavc... |
| - | Connectivi... | connectivi... |
| - | Adjuvant C... | adjuvantca... |
| - | ARTEFIN | artefin-ve... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.07.2019 | Series A | $56M | - |
Mentions in press and media 4
| Date | Title | Description |
| 23.07.2019 | X-Vax Technology Inks $56M Series A | JUPITER, FL, X-Vax Technology today announced that it has raised $56 million in an upsized Series A financing. >> Click here for more funding data on X-Vax Technology >> To export X-Vax Technology funding data to PDF and Exc... |
| 23.07.2019 | X-Vax Technology Secures $56M in Series A Financing | X-Vax Technology, Inc., a Jupiter, Fla.-based biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, raised $56m in an upsized Series A financing. Backers included: – Johnson & Joh... |
| 23.07.2019 | X-Vax Technology Raises $56 Million in Upsized Series A Financing to Advance Lead Herpes Vaccine Program | - |
| 23.07.2019 | X-Vax Technology Raises $56M Series A | X-Vax Technology, Inc. (X-VAX ™), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, today announced that it has raised $56 million in an upsized Series A financing with particip... |